Press Releases

H. Lundbeck A/S (Lundbeck) will present key pipeline data and patient perspectives from the phase II AMULET trial, investigating amlenetug as a potential new treatment option targeting the rare neurological disorder, multiple system atrophy (MSA), in tandem with recent natural history data, shedding light on early disease progression of the condition. Lundbeck today announced that pipeline data will be presented at the 2025 International MSA Congress in Boston, U.S., May 9-11. The d

Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a potential first-in-class treatment for geographic atrophy (GA).[1]   Geographic atrophy (GA) is an eye disease that can lead to irreversible vision loss.[2] It affects more than five million people worldwide, of which more than 40% are considered blind, [4]  severely impacting their independence, mental health and qualit

Alterity Therapeutics a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATH434 for the treatment of Multiple System Atrophy (MSA). This designation is intended to accelerate the development and review of novel investigational products such as ATH434 and recognizes its potential as an innovative approach to address the high unmet nee

Nutshell Therapeutics Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial in the United States for its NTS071, a novel small molecule allosteric reactivator targeting p53 Y220C mutation. NTS071 is an oral small molecule allosteric reactivator targeting p53 Y220C with a novel scaffold. It selectively binds to the p53 Y220C mutant protein, improving its thermal stability, thereby enhancing the mutant protein's ability to bind with DNA and restorin

TransCode Therapeutics, Inc, the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced further progress in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. To date, 13 patients have received at least one dose of TTX

S&E bio Co., Ltd., a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate a Phase 1b clinical trial of its investigational stroke therapy, SNE-101. This is the first exosome-based therapy in Korea to enter clinical trials, marking a major milestone in the country's biopharmaceutical landscape. S&E bio developed SNE-101 using a proprietary 3D culture system to op

Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, announces the successful completion of its acquisition of IFF Pharma Solutions. This strategic milestone marks a significant step forward in its ambition to become a leader in support of the global pharma markets. With this acquisition, and following that of Qualicaps in 2023, Roquette decisively strengthens its position as a key player in the health industry by i

Sandoz, the global leader in generic and biosimilar medicines, announced today that it has signed a global collaboration agreement with Shanghai Henlius Biotech, Inc. (Henlius, HKEX:02696) to commercialize a biosimilar of leading oncology therapy, ipilimumab. The agreement is milestone-based for a total consideration of up to USD 301 million, including an upfront payment of USD 31 million, and will target net reference-medicine sales of USD 2.5 billion[1]. Under the terms of the agr

Edgewood Oncology, a clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic malignancies and genetically-defined solid tumors, today announced the presentation of new preclinical data presented by Dana-Farber Cancer Institute and Hebrew University-Hadassah Medical School in support of an ongoing investigator-sponsored Phase 1 study of BTX-A51 in liposarcoma (LPS) at the American Association of Cancer Research (AACR) Annual Meeting taking place April 25

Bayer announced today initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing Glypican-3 (GPC3) in patients with advanced hepatocellular carcinoma (HCC). Oncofetal protein GPC3 is a membrane-associated proteoglycan which is overexpressed in 70-75% of HCC lesions making it an attractive target for targeted radionuclide therapy.1,2 The first-in-human, dose escalation study (NCT06764316